Preparation for Child Psych PRITE and Boards
Revision as of 15:55, 26 August 2022 by Eugene Grudnikoff MD (Talk | contribs) (Created page with "==Introduction== ==Dose Equivalence and Effect Size Meta-analysis== A useful meta-analysis was published in 2020 evaluating studies of acute symptoms of schizophrenia (1). *...")

(diff) ← Older revision | Latest revision (diff) | Newer revision → (diff)
Jump to: navigation, search

Introduction

Dose Equivalence and Effect Size Meta-analysis

A useful meta-analysis was published in 2020 evaluating studies of acute symptoms of schizophrenia (1).

  • A number of antipsychotics demonstrated 95% response (ED95) (near maximum reduction in symptoms) well below their maximum licensed dose. For example, risperidone, which is licensed to be used at 16mg/day, showed ED95 at 6.26 mg/day and aripiprazole at 11.5 mg/day, while haloperidol's ED95 was only 6.3mg/day.
  • At their respective ED95 dose, risperidone had an effect size (SMD) of 0.6 and aripiprazole 0.42.
  • Conversely there was no clear plateau in response for clozapine at 600 mg (SMD >1) and olanzapine at 20mg (SMD 0.5), suggesting that higher doses may produce further response


[1] Stefan Leucht, M.D. et.al. Dose-Response Meta-Analysis of Antipsychotic Drugs for Acute Schizophrenia Am J Psychiatry 2020; 177:342–353